Free Trial

Check-Cap (CHEK) Competitors

Check-Cap logo
$0.80 +0.01 (+1.04%)
Closing price 03:59 PM Eastern
Extended Trading
$0.79 -0.01 (-1.63%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CHEK vs. NXGL, XAIR, LFWD, NEPH, ALUR, IRIX, NRXS, DHAI, QTI, and CODX

Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include NEXGEL (NXGL), Beyond Air (XAIR), ReWalk Robotics (LFWD), Nephros (NEPH), Allurion Technologies (ALUR), IRIDEX (IRIX), NeurAxis (NRXS), DIH Holding US (DHAI), QT Imaging (QTI), and Co-Diagnostics (CODX). These companies are all part of the "medical equipment" industry.

Check-Cap vs.

Check-Cap (NASDAQ:CHEK) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.

Check-Cap received 369 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 61.46% of users gave Check-Cap an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.

CompanyUnderperformOutperform
Check-CapOutperform Votes
370
61.46%
Underperform Votes
232
38.54%
NEXGELOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

Check-Cap has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Check-Cap has a net margin of 0.00% compared to NEXGEL's net margin of -52.60%. Check-Cap's return on equity of 0.00% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
NEXGEL -52.60%-71.19%-34.79%

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 2.2% of NEXGEL shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 24.9% of NEXGEL shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, NEXGEL had 3 more articles in the media than Check-Cap. MarketBeat recorded 5 mentions for NEXGEL and 2 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.96 beat NEXGEL's score of 0.79 indicating that Check-Cap is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NEXGEL
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NEXGEL has higher revenue and earnings than Check-Cap. NEXGEL is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A-$17.57M-$3.00-0.27
NEXGEL$8.69M2.35-$3.16M-$0.50-6.02

Summary

Check-Cap and NEXGEL tied by winning 7 of the 14 factors compared between the two stocks.

Remove Ads
Get Check-Cap News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHEK vs. The Competition

MetricCheck-CapX IndustryMedical SectorNASDAQ Exchange
Market Cap$4.68M$12.45B$5.55B$7.86B
Dividend YieldN/A1.87%5.35%4.05%
P/E Ratio-0.2718.8723.4918.67
Price / SalesN/A7.85368.1387.32
Price / CashN/A11.9038.1634.64
Price / Book0.202.116.634.09
Net Income-$17.57M$344.53M$3.20B$246.93M
7 Day Performance-10.11%-8.49%-6.38%-3.79%
1 Month Performance-0.21%-12.75%-1.52%-6.75%
1 Year Performance-71.17%-2.62%7.30%-1.88%

Check-Cap Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHEK
Check-Cap
1.055 of 5 stars
$0.80
+1.0%
N/A-74.5%$4.68MN/A-0.2780Short Interest ↓
Gap Up
NXGL
NEXGEL
0.7123 of 5 stars
$3.09
+14.4%
N/A+9.2%$20.98M$6.73M-5.3310Upcoming Earnings
Gap Up
XAIR
Beyond Air
4.6722 of 5 stars
$0.28
+5.6%
$3.67
+1,194.3%
-84.3%$19.49M$3.02M-0.2770News Coverage
LFWD
ReWalk Robotics
2.3869 of 5 stars
$1.80
+4.7%
$9.00
+400.0%
-67.5%$19.13M$25.66M-0.7260
NEPH
Nephros
1.8257 of 5 stars
$1.60
+2.9%
$5.00
+213.5%
-21.5%$16.82M$14.16M-17.7230Gap Up
ALUR
Allurion Technologies
2.4633 of 5 stars
$3.43
-4.2%
$22.83
+565.7%
-92.8%$16.44M$34.75M-0.29501Earnings Report
Short Interest ↑
Analyst Revision
IRIX
IRIDEX
1.1611 of 5 stars
$0.95
-4.0%
$2.00
+110.5%
-66.8%$15.80M$48.43M-1.42120Earnings Report
High Trading Volume
NRXS
NeurAxis
N/A$2.19
-5.2%
N/AN/A$15.71M$2.46M-1.1919Gap Down
DHAI
DIH Holding US
1.2569 of 5 stars
$0.32
-17.8%
N/A-79.0%$15.29M$64.47M-1.08N/AShort Interest ↓
Positive News
High Trading Volume
QTI
QT Imaging
N/A$0.55
-8.3%
N/A-50.5%$14.92M$4.00M0.00N/ANews Coverage
Gap Up
CODX
Co-Diagnostics
3.5372 of 5 stars
$0.46
+0.6%
$1.50
+223.6%
-72.4%$14.80M$7.32M-0.34100Earnings Report
Gap Down
Remove Ads

Related Companies and Tools


This page (NASDAQ:CHEK) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners